Jonathan Chang
Stock Analyst at Leerink Partners
(0.58)
# 4,156
Out of 5,150 analysts
76
Total ratings
28.57%
Success rate
-21.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $7.25 | +79.31% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $19.27 | +289.21% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $28.18 | -4.19% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $33.73 | +119.39% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $35.93 | -69.38% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $13.42 | +280.03% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $9.15 | +719.67% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $5.63 | +788.10% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $101.19 | -70.35% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $2.08 | +476.92% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $10.18 | +155.40% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $8.55 | +227.49% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $12.74 | +316.01% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $7.25
Upside: +79.31%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $19.27
Upside: +289.21%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $28.18
Upside: -4.19%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $33.73
Upside: +119.39%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $35.93
Upside: -69.38%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $13.42
Upside: +280.03%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $9.15
Upside: +719.67%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $5.63
Upside: +788.10%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $101.19
Upside: -70.35%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $2.08
Upside: +476.92%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $10.18
Upside: +155.40%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $8.55
Upside: +227.49%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $12.74
Upside: +316.01%